Andera Partners’ Portfolio Company JenaValve Technology Acquired by Edwards Lifesciences

JenaValve Technology has signed an acquisition deal with Edwards Lifesciences. The company has made significant advancements in the treatment of aortic regurgitation (AR). Already available in Europe, FDA approval is expected by late 2025.

This acquisition highlights Andera Partners' ability to support highly innovative companies and its leadership in cardiovascular innovations. The deal represents a major milestone for Andera Partners, demonstrating its successful investment strategy.

JenaValve Technology, a pioneer in transcatheter treatment of AR, has been supported by Andera Partners since its inception. The firm has helped JenaValve achieve CE mark approval and publish notable clinical data.

Edwards Lifesciences, a leader in heart disease treatment, stated that the acquisition would bolster its leadership in structural heart innovation. The deal is subject to antitrust and foreign investment approvals.